Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dare Bioscience, Inc. - Common Stock (NQ:DARE)

2.515 +0.125 (+5.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dare Bioscience, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Dare Bioscience's Earnings Outlook
Via Benzinga
A Look Ahead: Dare Bioscience's Earnings Forecast
Via Benzinga
Insights into Dare Bioscience's Upcoming Earnings
Via Benzinga
DARE Stock Earnings: Dare Bioscience Beats Revenue for Q2 2024
DARE stock results show that Dare Bioscience beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Recap: Dare Bioscience Q4 Earnings
Via Benzinga
Dare Bioscience Earnings Preview
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Earnings Scheduled For March 31, 2025
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. 
Via Benzinga
DARE Stock Earnings: Dare Bioscience Misses EPS, Beats Revenue for Q1 2024
DARE stock results show that Dare Bioscience missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023
DARE stock results show that Dare Bioscience beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning! 
Via InvestorPlace
Daré Bioscience Highlights Efficacy Data From Treatment Candidate For Painful Menstruation
Daré Bioscience Inc (NASDAQ: DARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1 an investigational... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
FDA Gives Nod To Daré Bioscience's Trial Of Non-Hormonal Treatment For Dyspareunia, Seeks Additional Funding
Daré Bioscience Inc (NASDAQ: DARE) announced that the FDA has cleared its investigational new drug (IND) application for DARE-VVA1 as a non-hormonal treatment option for moderate to severe dyspareunia,... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.